Advertisement
Anadys will also present at the JMP Securities Research Conference onMonday, May 19, 2008 at 3:30 p.m. PDT (6:30 p.m. EDT) at the Ritz-CarltonHotel in San Francisco. James L. Freddo, M.D., Chief Medical Officer ofAnadys, will present an overview of Anadys and an update on its twodevelopment-stage product candidates, ANA598 and ANA773.
Advertisement
Each presentation will be webcast at the time of presentation and can beaccessed on the Investor Relations page of the Company's website athttp://www.anadyspharma.com. Listeners are encouraged to visit the websiteapproximately five minutes prior to each presentation to download or installany necessary software. A replay of the presentations will be availableapproximately one hour after the live webcasts conclude and will be availablethrough June 2, 2008.
About Anadys
Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical companydedicated to improving patient care by developing novel medicines in the areasof hepatitis C and oncology. The Company is developing ANA598, anon-nucleoside polymerase inhibitor for the treatment of chronic hepatitis Cand ANA773, an oral TLR7 agonist prodrug for cancer.
Safe Harbor Statement
Statements in this press release that are not strictly historical innature constitute "forward-looking statements." Such statements include, butare not limited to, references to Anadys' strategy, development programs, andability to develop novel medicines in the areas of hepatitis C and oncology.Such forward-looking statements involve known and unknown risks, uncertaintiesand other factors, which may cause Anadys' actual results to be materiallydifferent from historical results or from any results expressed or implied bysuch forward-looking statements. For example, the results of preclinicalstudies may not be predictive of future results, and Anadys cannot provide anyassurances that ANA598 or ANA773 will not have unforeseen safety issues, willhave favorable results in future clinical trials or will receive regulatoryapproval. Risk factors that may cause actual results to differ are discussedin Anadys' SEC filings, including Anadys' Form 10-K for the year endedDecember 31, 2007 and Anadys' Form 10-Q for the quarter ended March 31, 2008.All forward-looking statements are qualified in their entirety by thiscautionary statement. Anadys is providing this information as of this dateand does not undertake any obligation to update any forward-looking statementscontained in this document as a result of new information, future events orotherwise.
SOURCE Anadys Pharmaceuticals, Inc.
